Skip to main content

Table 3 Observed and/or reported adverse events during the first 7 days after the start of treatment

From: Efficacy of two artemisinin-based combinations for the treatment of malaria in pregnancy in India: a randomized controlled trial

Event ASSP (n = 125) N (%) ASMQ (n = 123) N (%) Total (n = 248) N (%) p-value
Anaemia (< 11 g/dL) 18 (14.4) 17 (13.8) 35 (14.1) 0.896
Weakness 22 (17.6) 19 (15.4) 41 (16.5) 0.648
Nausea 4 (3.2) 9 (7.3) 13 (5.2) 0.146
Vomiting 2 (1.6) 15 (12.2) 17 (6.9) 0.001
Headache 7 (5.6) 3 (2.4) 10 (4.0) 0.206
Diarrhoea 2 (1.6) 6 (4.9) 8 (3.2) 0.144
Dizziness 11 (8.8) 12 (9.8) 23 (9.3) 0.795
Lower abdominal pain 8 (6.4) 4 (3.3) 12 (4.8) 0.248
Pruritus 2 (1.6) 1 (0.8) 3 (1.2) 0.571
Tinnitus 5 (4.0) 5 (4.1) 10 (4.0) 0.979